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Cancer stem cells (CSCs) represent a minor population that have clonal tumor initiation and self-renewal
capacity and are responsible for tumor initiation, metastasis, and therapeutic resistance. CSCs reside in
niches, which are composed of diverse types of stromal cells and extracellular matrix components. These
stromal cells regulate CSC-like properties by providing secreted factors or by physical contact. Fibrocytes
are differentiated from bone marrow-derived CD14þ monocytes and have features of both macrophages
and ﬁbroblasts. Accumulating evidence has suggested that stromal ﬁbrocytes might promote cancer
progression. However, the role of ﬁbrocytes in the CSC niches has not been revealed. We herein report
that human ﬁbrocytes enhanced the CSC-like properties of lung cancer cells through secreted factors,
including osteopontin, CC-chemokine ligand 18, and plasminogen activator inhibitor-1. The PIK3K/AKT
pathway was critical for ﬁbrocytes to mediate the CSC-like functions of lung cancer cells. In human lung
cancer specimens, the number of tumor-inﬁltrated ﬁbrocytes was correlated with high expression of
CSC-associated protein in cancer cells. These results suggest that ﬁbrocytes may be a novel cell popu-
lation that regulates the CSC-like properties of lung cancer cells in the CSC niches.
© 2018 Published by Elsevier B.V.1. Introduction
Tumor tissue is not a simple aggregate of homogenous cancer
cells; rather, it is a complex cluster of various cell types, including
not only cancer cells but also stromal cells [1]. Even among cancer
cells, distinct phenotypic statuses that differ in functional attri-
butes often exist, which makes it difﬁcult to control their growth.
In such a situation of tumor-cell heterogeneity, cancer stem cells
(CSCs) represent a minor but important population that have been
shown to have clonal tumor initiation and self-renewal capacity
[2], and these stem cell-like properties are thought to be
responsible for tumor metastasis, recurrence, and therapeutic
resistance [3].
Thus far, various attempts have been made to target CSCs inMedicine and Rheumatology,
niversity, 3-18-15 Kuramoto-
ishioka).order to regulate the progression of cancer; however, applicable
treatment strategies have yet to be developed. This may be due in
part to the fact that CSCs reside in and are protected by niches
comprised of various stromal cells, providing desirable condition to
CSCs by direct cell-cell contact or by secreted factors. In this regard,
it is crucial to understand how these complex and specialized en-
vironments are formed, in order to control the fate of CSCs. Among
the cells that comprise the CSC niche, cancer-associated ﬁbroblasts
(CAFs), mesenchymal stem cells (MSCs), tumor-associated macro-
phages (TAMs), and myeloid-derived suppressor cells (MDSCs) are
reported to be important for maintaining the microenvironment
[3]. However, given that the composition and mechanisms under-
lying the CSC niche have not been fully elucidated, we hypothesized
that there are still as-yet-undiscovered cellular mechanisms un-
derlying the composition of the CSC niche.
Fibrocytes are a minor population of leukocytes that differen-
tiate from bone-marrow derived CD14þmonocytes. The distinctive
feature of these cells is that they have ﬁbroblast-like tissue
remodeling properties in addition to their original inﬂammatory
A. Saijo et al. / Cancer Letters 421 (2018) 17e2718properties of macrophages [4]. We recently found that ﬁbrocytes
contribute to the acquired resistance to anti-VEGF therapy in lung
cancer and malignant pleural mesothelioma by producing alter-
native angiogenic factors, such as FGF2 [5]. These results prompted
us to consider that ﬁbrocytes may also play a role in regulating
cancer growth by affecting CSCs, as CSCs are deeply involved in
drug resistance.
Under this hypothesis, we focused on ﬁbrocytes as a previously
unrecognized cell type involved in CSC niche.
2. Materials and methods
2.1. Cell lines
The human lung adenocarcinoma cell line A549 was purchased
from the American Type Culture Collection. The human small cell
lung cancer cell line SBC-5 was kindly provided by Drs. M. Tanimoto
and K. Kiura (Okayama University, Okayama, Japan). These cell lines
were authenticated and maintained according to previously pub-
lished methods [5,6].
2.2. Reagents
The anti-mouse IL-2 receptor b-chain monoclonal antibody TM-
b1 was supplied by Drs. M. Miyasaka and T. Tanaka (Osaka Uni-
versity, Osaka, Japan). Cisplatin was purchased from Wako Pure
Chemical (Osaka, Japan). Neutralizing antibodies to Chitinase 3-like
1 (CH3L1), growth differentiation factor 15 (GDF-15), osteopontin
(OPN), CC-chemokine ligand 2 (CCL-2), and CC-chemokine ligand 7
(CCL-7) were purchased from R&D Systems (Minneapolis, MN,
USA). Neutralizing antibodies to MMP-9 and CC-chemokine ligand
18 (CCL-18) were purchased from Abcam (Cambridge, MA, USA).
The plasminogen activator inhibitor-1 (PAI-1) inhibitor tiplaxtinin
was purchased from AdooQ BioScience (Irvine, CA, USA). The g-
secretase inhibitor DAPT was purchased from Sigma-Aldrich (St.
Louis, MO, USA). The AKT inhibitors LY-294002 and BKM-120 were
purchased from Wako Pure Chemical and AdooQ BioScience,
respectively.
2.3. Animals
Six-week-old male severe combined immunodeﬁcient (SCID)
mice were obtained from CLEA Japan (Tokyo, Japan). Mice were
maintained under speciﬁc pathogen-free conditions throughout
the study. All experiments were performed in accordance with the
guidelines established by the Tokushima University Committee on
Animal Care and Use. At the end of each experiment, the mice were
anesthetized with isoﬂurane and euthanized humanely by cutting
the subclavian artery. All experimental protocols were reviewed
and approved by the animal research committee of Tokushima
University, Japan.
2.4. In vivo subcutaneous xenograft model of human lung cancer
cells
For subcutaneous implantation, each SCIDmouse had the skin of
its bilateral ﬂanks shaved and sterilized using 70% ethanol. Various
numbers of A549 cells (1e10 104 cells per mouse) or SBC-5 cells
(1e2.5 105 cells per mouse) with or without either human
monocytes (2 105 cells per mouse) or ﬁbrocytes (2 105 cells per
mouse) were injected subcutaneously into the ﬂank of the mice.
The tumor volume was calculated using the formula,
lengthwidth squared 0.5. The frequency of cancer-initiating
cells (CICs) at four weeks after inoculation was calculated using
the ELDA software program [7]. The mice were killed humanelyunder anesthesia when the tumor volume exceeded 1000mm3. To
examine the effect of LY-294002 on the tumorigenic capacity of
A549 cells, A549 cells were pretreated with LY-294002 (10 mM) for
2 h before subcutaneous injection.2.5. Isolation of human monocytes and ﬁbrocytes
Humanmononuclear cells and ﬁbrocytes were isolated from the
peripheral blood of healthy volunteers according to previously
published methods [8]. Greater than 90% of cells prepared in this
methods were consisted of ﬁbrocytes as determined by the
expression of CD45, collagen I, and CXCR4 [8]. CD14þ monocytes
were puriﬁed from mononuclear cells by positive selection using
anti-CD14 antibody and an Auto MACS cell separator (Miltenyi
Biotech, Surrey, UK). Informed consent was obtained from all vol-
unteers, and the protocol was approved by the Institutional Review
Board (IRB) of Tokushima University Hospital (IRB approval num-
ber: 1586).2.6. Preparation of conditioned medium from human monocytes
and ﬁbrocytes
Human monocytes or ﬁbrocytes were suspended at
2.5 105 cells ml1 in DMEM containing 10% FBS. Two milliliters of
cell suspension were seeded into each well of a 6-well plate and
cultured for 24 h. The attached cells were washed three times with
PBS, and the medium was replaced with DMEM containing 0.1%
FBS. After 48 h, the conditioned medium (CM) was harvested. CM
was ﬁltered through a 0.22-mm ﬁlter (EMD Millipore, Darmstadt,
Germany) and stored at 80 C for further analyses.2.7. Sphere-forming assay
Cultured cells were trypsinized and passed through a 40-mm cell
strainer (Corning, New York, NY, USA) to form a single-cell sus-
pension. The cells were washed with PBS and suspended at
2 103 cells ml1 (A549), 5 102 cells ml1 (SBC-5), or 2 104 cells
ml1 (human ﬁbrocytes) in DMEM containing 0.1% FBS. The tumor
cell suspension (100 ml) was plated into eachwell of a 96-well ultra-
low-attachment plate (Corning). The same amount of cell suspen-
sion for ﬁbrocytes or CM of either monocytes or ﬁbrocytes was
added to each well and cultured for 14 days (A549) or 21 days (SBC-
5). Tumor spheres (>50 mm) were counted under a microscope BZ-
9000 (Keyence, Osaka, Japan). The sphere-forming efﬁciency (%)
was calculated as the number of spheres divided by the number of
single cells seeded [9].2.8. Quantitative reverse transcription polymerase chain reaction
Reverse transcription polymerase chain reaction (RT-PCR) was
performed according to a previously published method [5]. Human
glyceraldehyde-3-phosphate dehydrogenase mRNA was used as a
loading control. The speciﬁc PCR primer pairs used for each gene
are shown in Supplementary Table 1.2.9. MTT assay
Cells were plated into a 96-well plate at density of 5 103 cells
per well and allowed to adhere for 24 h in DMEM containing 10%
FBS. The cells were starved in DMEM containing 0.1% FBS for 24 h
and then treated with serial concentrations of cisplatin, LY-294002,
and BKM-120 for 48 h. After incubation, an MTT assay was per-
formed according to a previously published method [5].
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Experiments were performed using a Human XL Cytokine Array
Kit (R&D Systems) according to the manufacture's instruction.
Quantitative analyses were performed using the ImageJ plugin.
2.11. Detection of protein expression in cancer cells
Cells were seeded in 6-well plates and allowed to adhere for
24 h in RPMI 1640 containing 10% FBS. Cells were starved in serum-
free DMEM for 24 h and pretreated with LY-294002 (10 mM), BKM-
120 (10 mM), or vehicle for 2 h. Cells were then treated with OPN
(1 mg/ml), CCL-18 (100 ngml1), or CM from ﬁbrocytes for the
indicated durations. Whole-cell extracts from cancer cells were
isolated using M-PER (Pierce, Rockford, IL, USA) containing phos-
phatase and protease inhibitor cocktails (Roche, Basel,
Switzerland). The concentrations of proteins were determined us-
ing a TaKaRa BCA Protein Assay Kit (Takara Bio Inc., Shiga, Japan).
Samples of 200 mgml 1 of total proteins were used for an auto-
mated capillary western assay using Wes instruments (Protein
Simple, San Jose, CA, USA) according to the manufacturer's in-
structions. Primary antibodies against phospho-Akt (4060) and Akt
(9272) were purchased from Cell Signaling Technology (Beverly,
MA, USA).
2.12. Clinical study population
We collected 58 consecutive cases of surgically resected lung
cancer patients with stage IA-IIIA in 2012 at Tokushima University
Hospital. We retrospectively analyzed their outcomes from the
electronic medical records. Twenty-four of 48 adenocarcinoma
cases were further analyzed CSC-related protein expression on
cancer cell. The current study was approved by the IRB of
Tokushima University Hospital (IRB approval number: 2471), and
informed consent was obtained from all patients.
2.13. Immunohistochemical studies of the patient samples
Fibrocyte-like cells in the clinical specimens were identiﬁed
using anti-CD45 and anti-ﬁbroblast-speciﬁc protein 1 (FSP-1)
antibody as previously described [5]. The patients were divided into
two groups according to the receiver operating characteristic (ROC)
analysis of the number of stromal ﬁbrocyte-like cells
(Supplementary Fig. 1A and Supplementary Table 2); ﬁbrocytes-
high, 15 patients with 12.6 ﬁbrocyte-like cells per ﬁeld on
average; ﬁbrocytes-low, 43 patients with <12.6 ﬁbrocyte-like cells
per ﬁeld on average at 400 magniﬁcation in the tumor stroma.
Collagen deposition in the tumor tissues were analyzed using Azan
stain, and the blue color area of the tumor was measured using
ImageJ plugin. To detect the CSC-associated protein in lung cancer
cells, a rabbit anti-sex determining region Y-box 2 (Sox-2) poly-
clonal antibody (1:150 dilution, NB110-37235; Novus Biologicals,
Littleton, CO, USA), a rabbit anti-Nanog monoclonal antibody
(1:100 dilution, ab109250; Abcam), and a rabbit anti-octamer-
binding transcription factor 4 (Oct-4) polyclonal antibody (1:200
dilution, #2750; Cell Signaling Technology) were used. A human
testis seminoma tissue slide was used as a positive control (Gene
Tex, Irvine, CA, USA). A lung cancer tissue array (LC806) was pur-
chased from US Biomax, Inc. (Rockville, MD, USA).
The sections were re-incubated with an anti-rabbit secondary
antibody conjugatedwith peroxidase (ready to use; Nichirei, Tokyo,
Japan). Immunoreactivity was detected using the 3,30-dia-
minobenzidine Tetrahydrochloride (DAB) Liquid System (Nichirei),
and samples were counterstained with hematoxylin. Immunohis-
tochemical positivity was deﬁned as tissue in which >10% of tumorcells were positive for DAB. Images were acquired using a micro-
scope (BZ-9000; Keyence).
2.14. Statistical analyses
The data are shown as the mean± standard error of the mean
(SEM). Statistical analyses were performed using Student's t-test
with or withoutWelch's correction, or theMann-Whitney U test for
unpaired samples, as appropriate. A one-way analysis of variance
(ANOVA) followed by Tukey's multiple-comparison post-hoc test
was used for comparisons among more than two groups. The
overall survival (OS) and disease-free survival (DFS) was deﬁned as
the time fromdiagnosis of lung cancer to the date of death from any
cause and the time from date of surgery to the date of recurrence of
lung cancer or death from any cause, respectively. Patients who
were alive at the time of analyses were censored at the last known
date of follow-up. The survival was estimated using the Kaplan-
Meier method, and the log-rank test was used to assess differ-
ences in the survival distributions between groups. Multivariate
analyses were performed with the Cox proportional hazards model
to identify variables that were independently predictive of
outcome. Factors with p-values <0.05 on univariate analyses were
entered as candidate variables. Resulting p-values of <0.05 were
considered to be signiﬁcant. Statistical analyses were performed
using the GraphPad PRISM software program (5.01; GraphPad
Software, Inc., La Jolla, CA, USA) and R software (3.1.1; The R
Foundation for Statistical Computing).
3. Results
3.1. The accumulation of ﬁbrocytes in human lung cancer tissue
Initially, to determine whether or not ﬁbrocytes were involved
in lung cancer progression in clinical settings, we carried out
immunohistochemical studies with surgically resected samples
from lung cancer patients. Fibrocytes in the tissue section are
usually identiﬁed with the expression of a marker of ﬁbroblasts
such as collagen production together with the expression of CD34
and/or CD45 [4]. However, these approaches may include some
population of ﬁbroblasts and macrophages. Therefore, we used the
term of ﬁbrocyte-like cells in clinical settings and identiﬁed
ﬁbrocyte-like cells with both CD45 and FSP-1 expressed cells as
previously described [5]. The patients were divided into two groups
according to the ROC analysis of the number of stromal ﬁbrocyte-
like cells (See Material and Methods, and Supplementary Fig. 1A)
and the clinicopathological features were summarized in
Supplementary Table 2. We found that the survival of patients in
the ﬁbrocytes-high group was signiﬁcantly worse than in the
ﬁbrocytes-low group (Fig. 1A and B). As the interaction between
extracellular matrix (ECM) and tumor cells regulates cancer pro-
gression [10], and as ﬁbrocytes are known to produce collagen [4]
we analyzed collagen deposition, which is the main component of
the ECM, in tissue samples from lung adenocarcinoma patients.
However, the correlation between collagen deposition in the tumor
and number of stromal ﬁbrocyte-like cells was not found
(Supplementary Fig 1B). In the univariate analysis, clinical stage,
and gender were also signiﬁcantly associated with poor prognosis
(Table 1). Based on the results of univariate analysis, variables of the
number of stromal ﬁbrocytes, clinical stage, and gender were
applied into multivariate Cox proportional hazard regression
model, and all the variables were independent poor prognostic
factors in resectable lung cancer patients (Table 1). These results
indicated that proinﬂammatory properties rather than tissue
remodeling properties of ﬁbrocytes were involved in cancer pro-
gression in the tumor microenvironment of lung cancer.
Fig. 1. Fibrocytes promote the tumorigenic ability of lung cancer cells in vivo. A, Fibrocyte-like cells were identiﬁed using double immunohistochemistry, and representative images
of staining for CD45 (red) and/or FSP-1 (brown) in the section from resectable lung adenocarcinoma patients are shown. The arrow indicates double-positive cells. Scale bar upper
panels, 200 mm; scale bar lower panels, 50 mm. B, Kaplan-Meier estimates of the probability of a OS in the ﬁbrocytes-high group (n¼ 15, red line) and ﬁbrocytes-low group (n¼ 43,
blue line) were compared. The median OS was not reached in either group. There was a signiﬁcant difference in the OS between the two groups (hazard ratio, 3.36; 95% conﬁdence
interval, 1.03e10.91; P¼ 0.044). The P value was calculated using the log-rank test. C, A549 cells were implanted into SCID mice to form subcutaneous xenografts. Tumor volume
after subcutaneous injection of A549 (1 105 cells/mouse) with or without ﬁbrocytes is presented (n¼ 5 per group). D, The tumor formation rate after subcutaneous co-injection of
A549 (1 104 cells/mouse) with or without either human monocytes or ﬁbrocytes was evaluated (n¼ 5e7). The experiment was performed in duplicate. E, Gross appearances of the
tumors in mice 11 weeks after subcutaneous injection of A549 cells (5 104 cells/mouse) alone (upper) and with ﬁbrocytes (lower). All data are shown as the means ± SEM. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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in vivo
To further assess whether or not ﬁbrocytes enhanced tumor
growth of lung cancer cells, we isolated human ﬁbrocytes from
peripheral blood of healthy volunteers, and conducted an in vivo
study by subcutaneously injecting human lung adenocarcinoma
A549 cells (1 105 cells) with or without human ﬁbrocytes
(2 105 cells) into SCID mice. Human ﬁbrocytes were ﬁrst
conﬁrmed to be alive and resided in the tumor for 72 h after
inoculation into tumor-bearing mice (Supplementary Fig. 1C). Four
weeks after the injection, all mice developed subcutaneous tumors
(Table 2); however, no marked differences were seen in the tumorgrowth between two groups (Fig. 1C). We next assessed whether or
not ﬁbrocytes contribute to the tumor initiation of lung cancer cells.
When a small number of A549 cells (1 104 or 5 104 cells) was
injected with or without either human ﬁbrocytes (2 105 cells) or
monocytes (2 105 cells) into SCID mice, A549 cells co-injected
with ﬁbrocytes formed subcutaneous tumors earlier than those
co-injected with PBS or monocytes (Fig. 1D) and formed a larger
tumor at the endpoint (Fig. 1E). The frequency of CICs, which
display the properties of CSCs, at four weeks after the inoculation of
A549 cells was signiﬁcantly enhanced by co-injection with ﬁbro-
cytes compared with co-injection with PBS or monocytes (Table 2),
suggesting that the ﬁbrocytes were able to initiate tumor formation
of A549 cells via paracrine factors and/or cell-cell contact. Similar
Table 1
Univariate and multivariate analyses for death of lung cancer patients.
Variables Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Age
70 > vs. <70 1.13 (0.41e3.15) 0.809
Gender
Male vs. Female 3.48 (1.25e9.69) 0.017 4.88 (1.03e23.08) 0.046
Clinical stage
II, III vs. I 11.09 (3.17e38.82) 0.001 3.49 (1.19e10.26) 0.023
Smoking status
Smoker vs. Never-smoked 1.40 (0.62e3.19) 0.417
Number of ﬁbrocytes
high vs. low 3.36 (1.03e10.91) 0.044 2.90 (1.00e8.39) 0.050
HR, hazard ratio; CI, conﬁdence interval.
Overall survival was estimated using the Kaplan-Meier method, and the log-rank test was used to assess differences in the survival distributions between variables.
Table 2
The frequency of CICs in lung cancer cells in vivo.
A549 Tumor formation 1/CIC frequency (95% CI) P value
1 105 cells 5 104 cells 1 104 cells
Control 5/5 0/11 0/11 Inf (Infe220313)
0.248a
With monocytes 1/12 0/12 694701 (4910248e98286) 0.003b
0.030c
With ﬁbrocytes 5/5 4/12 2/12 100259 (226975e44286)
SBC-5 5105 cells 2.5105 cells 1/CIC frequency (95% CI) P value
Control 0/5 0/5 Inf (Infe1251781)
0.003b
With ﬁbrocytes 3/5 2/5 522460 (1287716e211975)
CI, conﬁdence interval.
The frequencies of CICs and P values were calculated using ELDA software program.
a Compared with control and monocyte.
b Compared with control and ﬁbrocyte.
c Compared with monocyte and ﬁbrocyte.
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line SBC-5 (Table 2).3.3. Enhancement of the sphere-forming ability of lung cancer cells
by ﬁbrocytes
Since in vivo results suggested the ability of ﬁbrocytes to pro-
mote CSC properties of lung cancer cells, we next assessed the
sphere-forming ability of lung cancer cells, which is one of the
functional methods for evaluating the properties of CSCs in vitro
[11]. A549 and SBC-5 cells were cultured with either CM from
monocytes or ﬁbrocytes in ultra-low-attachment plates. Although
these cells rarely formed tumor spheres when cultured with CM
from monocytes, the sphere-forming efﬁciency was signiﬁcantly
increased when these cells were cultured with CM from ﬁbrocytes
(Fig. 2A). Similar effect was observed using ﬁbrocytes from lung
cancer patients (Supplementary Fig 2A). These results suggested
that paracrine factor from ﬁbrocytes might promote CSC-like
properties of lung cancer cells.
To conﬁrm the CSC-like properties of sphere-forming cells
induced by ﬁbrocytes, the expression of the stemness-associated
genes Oct-4, Sox-2, and Nanog in sphere-forming cells was
assessed. The mRNA expression of these genes in sphere-forming
cells was signiﬁcantly upregulated compared with that in
parental cells (Fig. 2B). Drug resistance is also an important prop-
erty of CSCs [11]. Sphere-forming cells were more resistant to
cisplatin treatment than in parental cells (Supplementary Fig. 2B).
Furthermore, the mRNA expression of ABCG2 and ABCB1 genes,which are associated with resistance to multiple drugs, was
signiﬁcantly higher in sphere-forming cells than in parental cells
(Supplementary Fig. 2C). Sphere-forming cells displayed a signiﬁ-
cantly greater cancer-initiating capacity than parental cells (Fig. 2C
and Supplementary Table 3). These results further supported the
notion that soluble factors derived from ﬁbrocytes induced CSC-like
properties of lung cancer cells.3.4. Enhancement of CSC-like properties of lung cancer by
paracrine factors from ﬁbrocytes
To identify the factors secreted by ﬁbrocytes that enhanced the
CSC-like phenotype of lung cancer cells, we compared the cytokine
and chemokine proﬁles of ﬁbrocytes with that ofmonocytes using a
membrane-based protein array. Five secreted proteins were iden-
tiﬁed as more than ﬁve-fold increased in the CM of ﬁbrocytes
compared with that of monocytes from two different donors
(Fig. 3A and Supplementary Table 4). An oligonucleotidemicroarray
analysis was also performed, and 10 putative secreted genes were
identiﬁed that were signiﬁcantly upregulated (more than 200-fold)
in ﬁbrocytes compared with monocytes (Supplementary Table 5).
Based on these results, we focused on CH3L1, GDF-15, PAI-1,
OPN,MMP-9, CCL-2, CCL-7, and CCL-18 for future examinations. The
respective functions of these proteins in the sphere-forming ability
of lung cancer cells were assessed using neutralizing antibodies or
speciﬁc inhibitors. Although the results varied among ﬁbrocytes
donors, the neutralizing antibody for OPN and CCL-18 as well as
PAI-1 inhibitor reduced the ﬁbrocyte-mediated spheroid formation
Fig. 2. Soluble factor derived from ﬁbrocytes induced the CSC-like phenotype in lung cancer cells in vitro. A, A549 and SBC-5 cells were cultured with CM from either monocytes or
ﬁbrocytes in ultra-low-attachment plates. A representative image of tumor spheres is presented at left panel. Scale bar, 200 mm. The number of spheres with a diameter greater than
50 mmwas quantiﬁed on day 14 (A549) or day 21 (SBC-5). The quantitative analysis of sphere forming efﬁciency is shown in the right panel (n ¼ 4). The experiment was performed
in triplicate. *P< 0.05, and P values were calculated using Student's t-test with Welch's correction. B, A549 or SBC-5 cells were treated with CM from ﬁbrocytes under ultra-low-
attachment conditions for seven days, and the mRNA expression of CSC-associated genes in parental and sphere-forming cells was detected with a quantitative real-time PCR
analysis (n¼ 3). The experiment was performed in triplicate. P< 0.05, and P values were calculated using Student's t-test. C, Parental A549 cells or sphere-forming cells
(5 104 cells/mouse) were subcutaneously inoculated into SCID mice. The tumor formation rate after subcutaneous injection was evaluated (n¼ 5 per group). The experiment was
performed in duplicate. All data are shown as the means ± SEM.
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proteins did not inhibit the ﬁbrocyte-mediated spheroid formation
(Supplementary Fig. 3A). An additive effect of anti-OPN and anti-
CCL-18 antibody on ﬁbrocyte-mediated spheroid formation of
A549 cells was not observed (Supplementary Fig. 3B), suggesting
that these two proteins might share the intracellular signaling
pathways. g-Secretase is involved in OPN-CD44 signaling through
the release of CD44 C-terminal intracellular domain similar to
Notch signaling [12]. The g-secretase inhibitor DAPT inhibited the
ﬁbrocyte-enhanced sphere formation of A549 cells, further sup-
porting the involvement of OPN in the ﬁbrocyte-mediated sphere-
forming ability of A549 cells (Fig. 3B). However, recombinant OPN,
CCL-18, and PAI-1 did not enhance the sphere formation of lung
cancer cells (Supplementary Fig. 3C), even with combination
treatment, suggesting that although these proteins were secreted
by ﬁbrocytes, other unidentiﬁed factors may modify their ultimate
effect on spheroid formation [13,14].
3.5. Importance of the PIK3K/AKT pathway for ﬁbrocyte-mediated
CSC-like properties of lung cancer cells
OPN, CCL-18, and PAI-1 are reported to play important roles in
the tumor progression via the activation of the PI3/AKT pathway
[12,15e18], so we focused on the AKT pathway of lung cancer cells.
CM from ﬁbrocytes as well as recombinant OPN and CCL-18increased the phosphorylation of AKT protein of lung cancer
cells (Fig. 4A), and these effects were inhibited by the AKT in-
hibitors LY-294002 and BKM-120 (Fig. 4B and Supplementary
Fig. 4A). Furthermore, LY-294002 and BKM-120 signiﬁcantly
suppressed the ﬁbrocytes-mediated sphere-forming capacity of
lung cancer cells at a dose that did not affect the proliferation of
lung cancer cells in vitro (Fig. 4C and Supplementary Fig. 4B and
4C).
To validate the importance of the PI3K/AKT pathway in
ﬁbrocyte-mediated tumorigenesis in vivo, A549 cells were pre-
treated with LY-294002 prior to their subcutaneous injection into
SCID mice. Although the pretreatment of LY-294002 itself did not
affect the subcutaneous tumor growth of A549 cells
(1 105 cells/mouse), co-injection of ﬁbrocytes with a decreased
number of A549 cells (1 104 cells/mouse) pretreated with LY-
294002 signiﬁcantly reduced the tumor formation and fre-
quency of CICs (Fig. 4D and E, and Table 3). These results sug-
gested that the PI3K/AKT pathway was strongly associated with
the ﬁbrocyte-mediated acquisition of CSC-like properties of lung
cancer cells.
3.6. Association of the number of tumor-inﬁltrated ﬁbrocytes with
the CSC-like phenotype of lung cancer cells in clinical specimens
Finally, to assess the interaction between ﬁbrocytes and the
Fig. 3. Paracrine factors from ﬁbrocytes enhance the sphere-forming ability of lung cancer cells. A. Membrane-based protein arrays of CM from ﬁbrocytes and monocytes were
performed for two different donors. The representative image of the membrane is shown in the left panel. The mean pixel density of indicated cytokines from monocyte and
ﬁbrocyte was calculated using the Image J software program (right panel). B, The inhibitory effect of neutralizing antibodies for OPN (10 mg/ml) and CCL-18 (5 mg/ml) and the speciﬁc
inhibitor to PAI-1 (tiplaxtinin, 0.5 mM) and g-secretase (DAPT 5 mM) on the ﬁbrocyte-inducing sphere-forming ability of A549 cells was evaluated (n ¼ 4). The experiment was
performed in triplicate using CM from two different donors. *P< 0.05, and P values were calculated using Student's t-test. All data are shown as the means ± SEM.
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carried out immunohistochemical studies with surgically resected
samples from lung cancer patients. Sox-2 and Nanog protein
expression were reported to be an independent poor prognostic
factor in resectable lung adenocarcinoma patients [19,20], so we
investigated the expression of these proteins in our lung adeno-
carcinoma samples.
Among 24 adenocarcinoma tissues, 10 had positive staining for
Sox-2, with a positive rate of 41.6%, and 14 cases had positive
staining for Nanog, with a positive rate of 58.3%. These results
were consistent with previous reports [19,20]. Furthermore, the
number of ﬁbrocyte-like cells was signiﬁcantly higher in the
tumor-stroma of Sox-2 and Nanog-positive cases than in negative
cases (Fig. 5A). Unlike previous reports, the Sox-2 and Nanog
expression was not associated with the DFS in our study (date not
shown). Because Oct-4-positive cancer cells were rarely observed
in early-stage lung adenocarcinoma samples, we further analyzed
the Oct-4 expression using a lung cancer tissue array, which
contained a variety of lung cancer sections from various stages.
Twenty-nine cases of 72 lung cancer tissues were positive for Oct-
4 staining, with a positive rate of 40.3%. In addition, the number of
ﬁbrocyte-like cells was signiﬁcantly higher in the tumor stroma of
Oct-4-positive cases than that in Oct-4-negative cases (Fig. 5B).
These ﬁndings support our pre-clinical data suggesting that
ﬁbrocytes might be a pivotal cell that regulates the CSC-like fate of
lung cancer cells in the CSC niches.4. Discussion
Fibrocytes are differentiated from bone-marrow derived
monocytes and share the inﬂammatory features of macrophages
and tissue remodeling properties of ﬁbroblasts [21]. Based on their
inﬂammatory and ﬁbrogenic abilities, ﬁbrocytes were previously
reported to be involved in the pathogenesis of various ﬁbrotic
diseases, such as asthma and interstitial pulmonary ﬁbrosis [4,22].
In the tumor microenvironment, however, only a few studies have
reported their immunosuppressive role and tumor-promoting
ability [23e25], and the role of ﬁbrocytes in the tumor microen-
vironment is not fully elucidated. To our knowledge, we have
demonstrated for the ﬁrst time their role in CSC niches.
In CSC niches, CAFs are reported to be the most prominent cells
[26]. Fibrocytes are a distinct cell population from CAFs in that they
express hematopoietic cell markers CD34 and CD45, and chemokine
receptor CXCR4 [21]. However, completely distinguishing these cell
types in the tissue seems difﬁcult for several reasons. First, CAFs are a
heterogeneous cell-subset and largely deﬁned based on the
expression of a-smooth muscle actin, ﬁbroblast activation protein,
and platelet-derived growth factor receptor-b [27]. These markers
are not speciﬁc to CAFs and can also be expressed by ﬁbrocytes
[4,28]. Second, some studies have shown that bone marrow-derived
precursor cells contribute to the CAF population in addition to local
ﬁbroblasts [29], suggesting that ﬁbrocytes may have been included
in the heterogeneous CAF subsets in previous studies.
Fig. 4. Fibrocytes enhance the CSC-like properties of lung cancer cells via the PIK3K/AKT pathway. A, A549 and SBC-5 cells were cultured with OPN (1 mg/ml), CCL-18 (100 ngml1),
or CM from ﬁbrocytes for the indicated duration. The phosphorylation of AKT was detected by an automated capillary western assay. Total AKT was used as the loading control. B,
A549 cells were pretreated with the AKT inhibitors LY-294002 (20 mM) or BKM-120 (10 mM), or vehicle for 2 h. Cells were then treated with CM from ﬁbrocytes for 30min. The
phosphorylation of AKT was detected by an automated capillary western assay. Total AKT was used as loading control. C, A549 cells were cultured in CM from ﬁbrocytes with or
without either LY-294002 (1 mM) or BKM-120 (250 nM) on an ultra-low-attachment palate. The representative image of tumor cells in each well is shown in the upper panel. Scale
bar, 200 mm. The number of spheres with a diameter greater than 50 mm was quantiﬁed on day 14, and the sphere-forming efﬁciency is shown in the lower panel (n ¼ 4). The
experiment was performed in triplicate. *P< 0.05, and P values were calculated using a one-way ANOVA followed by Tukey's post hoc test. D, A549 cells were pretreated with DMSO
or LY-294002 (10 mM) for 2 h. A549 cells (1 105 cells/mouse) were then subcutaneously injected into the ﬂank of SCID mice. The tumor volumes after subcutaneous injection are
shown. (n¼ 6 per group). E, A549 cells were pretreated with DMSO or LY-294002 (10 mM) for 2 h. A549 cells (1 104 cells/mouse) were then subcutaneously co-injected with
human ﬁbrocytes into the ﬂank of SCID mice. The tumor formation rate after subcutaneous injection is shown (n¼ 6 per group). All data are shown as the means ± SEM.
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clinical specimens, macrophages can be identiﬁed from cancer cells
using CD68 or myeloid cell surface markers, CD14, HLA-DR, CD312,
CD115, and CD16. TAMs are further phenotyped using M2 subset-
speciﬁc markers, including CD163, CD204, and CD301, and the
tolerogenic macrophage-expressed scavenger receptor CD206 [31].
These markers are not static and can be changed by the tumor
microenvironment [31]. Both ﬁbrocytes and TAMs aredifferentiated from bone marrow-derived CD14þ precursor cells
and express common cell surface markers, including CD11b, CD68,
CD163, and CD206 [1]. Furthermore, on stimulation with GM-CSF
or M-CSF, the expression of collagen on ﬁbrocytes was found to
be downregulated, and ﬁbrocytes were differentiated into macro-
phages [32]. These ﬁndings suggested that ﬁbrocytes can differ-
entiate into a TAM subset in response to changes in the tumor
microenvironment in CSC niches andmight havemade up a portion
Table 3
The frequency of CICs in A549 cells in vivo.
A549 Tumor formation 1/CIC frequency (95% CI) P value
1 105 cells 5 104 cells 1 104 cells
With PBS Vehicle 6/6 1/5 63771 (137828e29507)
1.000
LY-294002 6/6 1/5 63771 (137828e29507)
With ﬁbrocyte Vehicle 5/6 5582 (15150e2057)
0.016
LY-294002 1/6 54849 (390430e7706)
CI, conﬁdence interval.
The frequencies of CICs and P values were calculated using ELDA software program.
Fig. 5. The number of tumor-inﬁltrated ﬁbrocyte-like cells is associated with the CSC-like phenotype of lung cancer cells in clinical specimens. A, The representative images of
negative or positive staining for Sox-2 or Nanog in tumor cells are shown in the upper panel. Scale bar, 200 mm. Lung adenocarcinoma patients were divided into two groups
according to the expression of Sox-2 or Nanog in the tumor cells, and the number of stromal ﬁbrocyte-like cells was compared between the two groups (n ¼ 24, lower panel).
*P< 0.05, and P values were calculated using Student's t-test with Welch's correction. B, The expression of Oct-4 in tumor cells and the number of ﬁbrocyte-like cells in tumor
stroma was assessed using a lung cancer tissue array. The representative images of negative or positive staining for Oct-4 in tumor cells are shown in the upper panel. Scale bar,
200 mm. The number of stromal ﬁbrocyte-like cells in the Oct-4-negative group and Oct-4-positive group were compared (n ¼ 72, lower panel). *P < 0.05, and P values were
calculated using Student's t-test with Welch's correction. All data are shown as the means ± SEM.
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A previous study showed that MDSCs isolated from human
breast cancer enhanced the CSC-like properties of breast cancer
cells by activating STAT3 and NOTCH [33]. MDSCs comprise a het-
erogeneous population of bone marrow-derived cells that include
diverse states of differentiation, from early myeloid to a more
granulocytic or monocytic phenotype [34]. Recently, CCR2þMDSCs
subset were found to be differentiated into ﬁbrocytes and pro-
moted tumor metastasis [35]. Furthermore, circulating ﬁbrocytes
were reported to have features of an MDSC subset, such as immune
evasion, and contributed to tumor progression [24]. Thus, both
MDSCs and ﬁbrocytes include heterogeneous populations and have
common features and origins. In addition, the molecular markers
that distinguish these cells have not clearly been established.
Therefore, further studies to investigate theMDSC-like features and
molecular markers of the MDSC subset among ﬁbrocytes in CSCniches are needed.
The present study demonstrated that ﬁbrocytes regulate the
CSC-like properties of lung cancer cells by providing OPN, CCL-18,
and PAI-1. OPN is a small integrin-binding ligand N-linked glyco-
protein and is produced by both CAFs and TAMs [13,26,36]. OPN
secreted from CAFs increased the CSC population of colorectal
cancer cells by activating the PI3K/AKT pathway [37]. Furthermore,
OPN produced from TAMs facilitated the tumorigenicity of CD44-
positive colorectal cancer cells via c-jun-NH2-kinase signaling
[38]. Thus, OPN appears to be one of the most important factors
derived from host cells in the CSC niche. CCL-18 is a chemokine
predominantly produced by TAMs and highly expressed in lung
with several pathologies, including malignancy and ﬁbrosis [39].
CCL-18 enhanced metastasis by inducing epithelial to mesen-
chymal transition (EMT) in lung and breast cancer via the activation
of the AKT/GSK3b pathway [16,39e41]. EMT endows CSC-like
A. Saijo et al. / Cancer Letters 421 (2018) 17e2726properties in mammary epithelial cells [42]. Thus, CCL-18 is also a
niche-cell-derived factor that promotes a CSC-like fate. These
ﬁndings suggest that ﬁbrocytes may be a novel cell population that
facilitate the induction of CSC-like properties in lung cancer by
producing OPN and CCL-18 in CSC niches.
PAI-1 is a secreted protein that inhibits urokinase-type plas-
minogen activator (u-PA) and plays an important role in the
plasminogen-plasmin system [43]. The proteolytic enzyme plasmin
is activated by u-PA and facilitates tumor migration and invasion by
the degradation of the ECM and activation of latent growth factors
[14]. Earlier studies have therefore suggested that PAI-1 might
suppress tumor progression. However, a high PAI-1 expression of
tumor was found to be associated with a poor prognosis in many
types of cancer. Recent studies have demonstrated that PAI-1
inhibited cell apoptosis by inactivating caspase-3 or upregulating
the PI3K/AKT and Jak/STAT pathways [44]. Furthermore, PAI-1
induced the expression of EMT marker by activating the AKT and
ERK1/2 pathways in lung cancer [18]. Taken together, these ﬁndings
suggest that PAI-1 might promote tumor progression rather than
tumor inhibition through an anti-proteolytic effect in the tumor
microenvironment and may be a niche-cell-derived factor that
regulates the CSC-like properties of cancer cells.
In summary, we identiﬁed ﬁbrocytes as a novel cell population
regulating the CSC-like properties of lung cancer by activating the
AKT pathway thorough secreted factors, including OPN, CCL-18,
and PAI-1. Although targeting the AKT pathway may provide a
therapeutic strategy against CSCs, a further understanding of the
CSC niche factors that regulate both CSC-like phenotype of lung
cancer cells and recruitment of ﬁbrocytes into CSC nichemight help
to develop a successful treatment strategy targeting CSCs.
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